AtorvaStatin Postpartum and Reduction of Cardiovascular risK

Summary

The objective is to conduct a double-blinded randomized controlled trial of atorvastatin vs. placebo among postpartum individuals with hypertensive disorders of pregnancy, to improve cardiovascular risk score postpartum. For this, 76 individuals with hypertensive disorders of pregnancy (HDP) will be randomized to atorvastatin 10mg or placebo, which will be started in the postpartum period after cessation of breast feeding and continued for 3 months.

Timeline

Start

2025-10-03

Primary completion

2026-09-15

Completion

2026-12-15

Drugs

Indications